Peptide SDS Requirements in Australia: A Laboratory Guide

In Australia, a safety data sheet (SDS) is legally required for a research peptide only when the peptide is classified as a hazardous chemical, but laboratories should obtain one for every peptide they receive. The document must follow the 16-section GHS format, be written in English, carry Australian contact details and be reviewed at least every five years. Where hazard data are incomplete, which is common for novel synthetic peptides, the work health and safety (WHS) framework allows the SDS to say so, provided it directs a precautionary approach to handling and storage. This guide sets out what the obligations are, what a credible peptide SDS looks like, and how to audit one before a vial enters the laboratory.

Who must prepare a peptide SDS, and who must hold one

The duty to prepare an SDS rests with manufacturers and importers. Safe Work Australia states that an SDS must be prepared for every hazardous chemical a business manufactures or imports, subject to a limited set of exceptions. A supplier that imports lyophilised peptide from overseas therefore carries the preparation duty for that product, while a downstream reseller or the end laboratory carries duties relating to access, storage and use.

The duties divide as follows:

• Manufacturer or importer: prepares the SDS, keeps it current, and supplies it with, or before, the first supply of the chemical.
• Supplier: passes on the current SDS and ensures the product label corresponds to it.
• Person conducting a business or undertaking (PCBU), including a university or research institute: keeps the SDS for each hazardous chemical readily accessible to workers, and uses it in the risk assessment.

At the institutional level the expectation is explicit. The UNSW hazardous chemicals procedure, for example, requires that the SDS for each hazardous chemical be readily accessible and available near the work area at all times, with an electronic system acceptable only if that condition is still met. A laboratory that stores SDS files solely in a procurement inbox does not satisfy this.

Is a research peptide a hazardous chemical?

The answer depends on classification under the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) as adopted in Australia, not on the product category. A peptide is hazardous for WHS purposes if it meets the criteria for a hazard class such as acute toxicity, skin or eye irritation, respiratory sensitisation or reproductive toxicity. Many short, well-characterised peptides are not classified as hazardous on available data. Several supplier SDSs that rank for this topic state that no known hazards are identified, while still noting that inhalation may cause respiratory tract irritation.

This produces a practical point that is often missed. A "not classified" outcome is not a statement of safety. The Safe Work Australia code of practice warns against vague wording and asks authors to distinguish between a case where no hazard information is available and one where testing has returned negative results. For a novel peptide the honest entry is frequently "toxicological properties not fully investigated", and a reader should treat that phrase as an instruction to apply the precautionary principle.

For pure peptide solids, the realistic exposure routes in a laboratory are:

1. Inhalation of fine lyophilised powder when a vial is opened, weighed or transferred.
2. Dermal and ocular contact during reconstitution.
3. Exposure to residual process solvents such as acetonitrile, or to counter-ions such as trifluoroacetate, which may be listed under composition.
4. Percutaneous exposure from needles and syringes used during reconstitution and aliquoting.

The 16 sections an Australian SDS must contain

The format is fixed. As described by Safe Work Australia, an SDS uses 16 standard sections, which are listed below with what a reader should look for in a peptide context.

Additional formal requirements apply to the document as a whole. Under the WHS framework summarised by WorkSafe Queensland, the SDS must be in English, use Australian legal units of measurement, state the date it was last reviewed (or prepared, if never reviewed), and give the name, Australian address and business telephone number of the manufacturer or importer, together with an Australian emergency number. A sheet that lists only an overseas manufacturer and an American poison-control line does not meet this standard.

When full hazard data are unavailable

Research peptides are often custom or newly synthesised, so complete toxicological data seldom exist. The WHS Regulations anticipate this. Schedule 7 of the model regulations, as applied in institutional guidance such as the UNSW procedure, treats research chemicals, samples for analysis and waste differently from ordinary commercial products. Where it is not reasonably practicable to provide full hazard information, the SDS may state that the information is unavailable, provided the identity or structure of the substance is given as far as practicable and the document directs precautionary handling and storage.

In practice, a laboratory receiving a peptide under this provision should:

• record the data gap in the chemical register and the risk assessment;
• default to controls appropriate for a potent, unknown compound (weighing in a ventilated enclosure, double gloving where appropriate, no open-bench handling of powder);
• restrict access to trained personnel; and
• review the control measures when new data are published or supplied.

The model regulations are available as the consolidated Model WHS Regulations (September 2024). Each state and territory enacts its own version, so the authoritative text for a given site is the local regulation.

Review cycle and what a stale SDS looks like

An SDS must be reviewed at least once every five years, and the review date must appear on the document. The same period applies to a sheet that has never been revised: the preparation date then acts as the clock. When assessing a peptide SDS, three indicators suggest it is unreliable:

• The date is older than five years, or absent.
• The sheet is written for another jurisdiction (for example, it cites only the US Hazard Communication Standard) and has no Australian contact.
• The same text is reused for chemically different peptides, with only the product name altered.

Some sheets that appear in search results state that a product is "not considered hazardous" under a US standard. That is a statement about a different legal framework and does not substitute for Australian classification.

Why an SDS does not settle the regulatory status of a peptide

An SDS answers a workplace safety question. It does not answer whether a peptide may lawfully be imported, supplied or used. In Australia that question is partly one for the Therapeutic Goods Administration (TGA) and partly for the Australian Industrial Chemicals Introduction Scheme (AICIS).

TGA

The TGA states that peptide products are regulated as therapeutic goods under the Therapeutic Goods Act 1989, and that unapproved products have not been assessed for safety, quality or effectiveness. The same alert states that a "research use only" or "not for human use" label does not alter a product's regulatory status if it is in fact a therapeutic good, and does not remove obligations relating to import, supply or advertising. Responsibility follows the nature and intended use of the substance, not the wording on the label. An overview of the framework is available on the TGA page on how therapeutic peptide products are regulated.

For a laboratory, the consequence is straightforward: a compliant SDS and a research-use label are necessary documentation for bench work, not authorisation for any human or veterinary application. The same TGA alert lists adverse events reported with unapproved peptides, including severe allergic reactions requiring hospitalisation, systemic inflammatory response syndrome and tendinitis. Anyone considering personal use should consult a registered medical practitioner, not rely on supplier paperwork.

AICIS

Industrial chemicals introduced into Australia are subject to AICIS, but therapeutic goods are excluded from that scheme and fall under TGA oversight. Where a peptide is introduced purely as an industrial chemical for research and development, AICIS provides categories with reduced obligations. The AICIS guidance on introductions categorised as exempted sets volume and physical-form conditions: for example, up to 250 kg in a registration year where the chemical is not introduced as a solid or in a dispersion. The same page notes that an SDS or product information sheet can be used as evidence of the chemical's physical form. For a solid lyophilised peptide, importers should read the criteria for their specific case rather than assume the 250 kg figure applies.

The SDS therefore has a second function: it is part of the evidence an importer relies on when categorising an introduction. Errors in Section 9 (physical form) can have regulatory, not just safety, consequences.

A procurement checklist for peptide SDS and supporting documents

The following checks can be applied to any supplier before an order is placed. They also help with the diligence described in the Au Peptide Labs guides on local peptide sourcing and identifying counterfeit peptides.

1. Identity match. The product name, sequence or CAS number on the SDS matches the label and the certificate of analysis (COA).
2. Australian details. An Australian address and an Australian emergency telephone number appear in Section 1.
3. Date. The sheet shows a preparation or review date within five years.
4. Classification statement. Section 2 gives either a GHS classification or a clear statement of non-classification, without vague wording.
5. Data gaps declared. Section 11 distinguishes untested endpoints from negative results.
6. Composition. Section 3 identifies the salt form and any residual solvents, which should be consistent with the COA.
7. Storage guidance. Section 7 gives a temperature range for lyophilised and reconstituted material.
8. Batch-specific COA. Purity is verified by an independent analytical report tied to the batch number, not by a general product claim.
9. Use statement. The documents state that the product is for laboratory research only and make no therapeutic claims.

What purity documentation adds to the SDS

An SDS describes hazards, not quality. Purity and identity are demonstrated by a COA, typically combining reverse-phase HPLC for purity and mass spectrometry for molecular identity. Facilities that characterise peptides stress that sample preparation determines whether results are usable. The Macquarie University analytical facility, for instance, lists quantitation and identification of peptides and proteins among its capabilities, and its guidance for elemental microanalysis asks for roughly 2 to 5 mg for a duplicate CHN/CHNS run, around 10 mg for thermal analysis (with up to 50 mg preferred), accurate expected mass percentages on the submission form, and samples free of interferences such as halides.

Those figures matter for laboratories that wish to verify a supplier's COA independently. A 10 mg vial leaves little material for confirmatory testing, so verification plans should be settled before reconstitution, and a retained portion should be stored under the conditions in Section 7 of the SDS.

Storage, handling and disposal controls drawn from the SDS

The SDS is only useful if its content reaches the bench. A defensible local procedure usually includes:

• Receipt: inspect the vial seal and label against the SDS and COA, record the batch number and date received, and file the SDS where workers can reach it.
• Storage: keep lyophilised peptide at the temperature stated in Section 7, protected from light and moisture; label reconstituted aliquots with date, concentration and diluent.
• Reconstitution: use the diluent specified in the product documentation, for example bacteriostatic water for multi-use research vials, and manage sharps with an approved container.
• Spills: follow Section 6, avoiding dry sweeping that would generate dust.
• Disposal: follow Section 13 and the institutional chemical waste procedure, since state and territory rules differ.
• Transport: check Section 14 and the carrier's conditions. The Au Peptide Labs guides on peptide shipping in Australia and peptide packaging materials cover the practical side.

Our perspective

We see the SDS as the first document a laboratory should read and the one most often skimmed. Our view is that a peptide supplier operating in Australia should be able to give a researcher three things together: a batch-specific, independently tested purity report, a current SDS with Australian contact details, and an unambiguous statement that the product is intended for laboratory research only. Each document answers a different question (what the material is, how to handle it, and what it may be used for), and none replaces the others.

Our positioning rests on 99%+ purity verified by third-party testing with a COA for every batch, dispatch from Melbourne within one business day, and discreet packaging. Domestic stock removes the import step and the customs delay that comes with it, which also reduces the time a vial spends in transit conditions before it reaches storage. We recommend that laboratories request the SDS and COA before ordering, compare the batch number on both, and file them together. Where a document is missing, out of date or inconsistent, the sound course is to withhold the order until it is corrected.

— Dr. Authur

Sourcing peptides and supplies with documentation

Laboratories that need peptides and the consumables used in reconstitution can browse the Au Peptide Labs Lab Supplies category, which includes insulin syringes, alcohol wipes and bacteriostatic water, alongside the research categories on the main store. Express Post is listed at $10 as a one-off fee. All products are sold strictly for laboratory research and not for human or veterinary use. Bulk and custom orders are available on request.

Frequently asked questions

Does every research peptide need an SDS in Australia?

An SDS is mandatory for hazardous chemicals, and the importer or manufacturer must prepare it. Many peptides are not classified as hazardous on available data, but laboratories should still request an SDS for each peptide, because it records handling, storage and first-aid information and documents any data gaps. Many institutional procedures also require one for every chemical held.

How often must a peptide SDS be updated?

An SDS must be reviewed at least once every five years, and the sheet must show the date of the last review or, if it has never been reviewed, its preparation date. It should be revised sooner if significant new hazard information becomes available. A sheet without a date should be treated as non-compliant.

Can an SDS say that a peptide's hazards are unknown?

Yes, in limited circumstances. For research chemicals, the WHS Regulations allow the SDS to state that full information is unavailable where providing it is not reasonably practicable, as long as the identity is given as far as practicable and a precautionary approach to handling and storage is specified. The statement must be clear, not a vague claim that the product is harmless.

Does a "research use only" label exempt a peptide from TGA rules?

No. The TGA states that such labels do not change the regulatory status of a product that is in fact a therapeutic good, and they do not remove obligations for import, supply or advertising. Regulatory responsibility follows the substance and its actual use. If you are unsure about the status of a specific peptide, contact the TGA or seek advice from a regulatory specialist.

Where can I check the format of an SDS?

Safe Work Australia publishes guidance on preparing safety data sheets and a model code of practice that set out the 16 sections and content expectations. State and territory regulators, such as WorkSafe Queensland, publish equivalent guidance for their jurisdictions. Your institution's WHS or chemical safety office can also confirm local requirements.

Sources

• Preparing safety data sheets, Safe Work Australia
• Preparation of safety data sheets for hazardous chemicals, model code of practice
• Model Work Health and Safety Regulations, 1 September 2024
• Labelling and safety data sheets, WorkSafe Queensland
• HS332 Hazardous Chemicals Procedure, UNSW
• Understanding your responsibilities when importing, compounding and supplying unapproved peptide products, TGA
• How we regulate therapeutic peptide products, TGA
• Step 2: Introductions that are categorised as exempted, AICIS
• Capabilities, Macquarie University analytical facility

Recommended

• Peptide packaging materials: the Australian lab guide
• Peptide shipping in Australia: what labs need to know
• Local peptide sourcing in Australia: what to verify before you order
• Peptide hygroscopicity: a lab guide for researchers